BENJAMIN MUSHER to Adenocarcinoma
This is a "connection" page, showing publications BENJAMIN MUSHER has written about Adenocarcinoma.
Connection Strength
1.861
-
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024 Apr; 25(4):488-500.
Score: 0.553
-
Identification of Educational Gaps Among Oncologists Who Manage Patients with Pancreatic Cancer. J Gastrointest Cancer. 2019 Mar; 50(1):84-90.
Score: 0.389
-
Single-Agent Immunotherapy for Two Types of Cancer in One Patient. Ann Intern Med. 2019 02 05; 170(3):210-211.
Score: 0.377
-
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res. 2019 Sep 15; 25(18):5493-5502.
Score: 0.099
-
Prognostic Value of Nodal Response After Preoperative Treatment of Gastric Adenocarcinoma. J Natl Compr Canc Netw. 2019 02; 17(2):161-168.
Score: 0.097
-
National Trends in Multimodality Therapy for Locally Advanced Gastric Cancer. J Surg Res. 2019 05; 237:41-49.
Score: 0.097
-
Prognostic value of neoadjuvant treatment response in locally advanced rectal cancer. J Surg Res. 2018 06; 226:15-23.
Score: 0.090
-
Oncolytic viral therapy for pancreatic cancer. J Surg Oncol. 2017 Jul; 116(1):94-103.
Score: 0.085
-
Pancreatic cancer disparities in African Americans. Pancreas. 2015 May; 44(4):522-7.
Score: 0.075